None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients older than 18 years and younger than 80 years 2. Patients with solid pancreatic/peripancreatic mass which is needed pathologic confirmation
Exclusion criteria
Exclusion criteria: 1. cystic pancreatic lesions without the evidence of solid component suspected with malignant transformation 2. cardiopulmonary instability 3. severe coagulopathy (international normalized ratio > 1.5 or platelet count < 50,000 cells/cubic millimeter [cmm3]) 4. inability to suspend antithrombotic therapy 5. pregnancy 6. Patients with underlying co-morbidities preclude sedation 7. GI obstruction or previous stomach surgery that preclude EUS examination 8. refusal to provide informed consent or participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the procurement rates of histologic cores that the cyto-pathologist considered to be of optimal quality for histological evaluation | — |
Secondary
| Measure | Time frame |
|---|---|
| diagnostic performance: diagnostic accuracy, sensitivity, specificity, positive predictive value, negative predictive value | — |
Countries
Korea, Republic of
Contacts
Asan Medical Center